Big biotech stock Amgen's (NASDAQ:AMGN) in no short supply of optimism for eager investors. Despite the company's so-so earnings projections going forward, it's thrived behind star drugs Enbrel and Neulasta, which have shown no signs of slowing down their blockbuster pace. That financial strength has propelled Amgen's stock to a gain of more than 34% over the past year, but the company's sturdy pipeline could be ready to deliver another dose of good news.
Amgen's developmental PCSK9 inhibitor evolocumab struck gold in a recent clinical trial, and this up-and-coming cholesterol-fighting drug's fueling high hopes of a new blockbuster to add to Amgen's drug portfolio. The cholesterol medication niche isn't a small one, however, and rival drugs from Regeneron (NASDAQ:REGN) and Pfizer (NYSE:PFE), among others, are racing against Amgen to capture the PCSK9 crown -- and the huge opportunity that comes with it -- in the near future.
Can Amgen's evolocumab make it to the market and become investors' next big hope for this star-studded big biotech? Find out what you need to know in the video below, as Motley Fool contributor Dan Carroll takes you through this promising health-care niche -- and why Amgen and its investors are poised to score big if evolocumab can win over regulators.
Can this under-the-radar opportunity spark your portfolio's riches?
Amgen's long been a top performer in biotech, and as its investors know, there's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
Dan Carroll and The Motley Fool have no position in any stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.